{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:38Z","timestamp":1794047498771,"version":"4.8.0"},"reference-count":19,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Functional high-risk (FHR) multiple myeloma (MM) patients, defined as those with early relapse despite optimal initial therapy, represent an unmet clinical need. Diffusion-weighted whole-body MRI (DW-MRI) is increasingly used in MM management due to its high sensitivity in assessing treatment response. The Myeloma Response Assessment and Diagnosis System (MYRADS) established the Response Assessment Category (RAC), a 5-point scale ranging from complete response (RAC 1) to progressive disease (RAC 5), which independently stratifies patients with different outcomes after autologous stem cell transplantation (ASCT). The relative fat fraction (rFF), derived from DW-MRI, provides additional prognostic insights into bone marrow composition. This study aimed to evaluate whether the combined assessment of RAC and rFF could identify FHR MM patients at risk of early relapse, defined as progression within 18 months post-autologous stem cell transplantation (ASCT). Ninety-seven MM patients were retrospectively analyzed after ASCT, before maintenance, with a median follow-up of 47 months. An rFF threshold of 17.2% predicted early relapse with 83% sensitivity and 85% specificity. Patients with rFF &gt;17.2% had significantly improved post-ASCT progression-free survival (PFS, median not reached [NR] vs. 13.7 months, HR 0.18; 95% CI: 0.08-0.43) and overall survival (OS, 3-year rate: 96% vs. 62%, HR 0.12; 95% CI: 0.03-0.45) compared to rFF \u226417.2%. Patients with RAC 1\/rFF High had the best outcomes, while RAC \u22652\/rFF Low had the worst prognosis (median PFS: NR vs. 12.3 months, HR 0.21; 95% CI: 0.07-0.62). rFF complements RAC for response assessment after ASCT, enabling early identification of FHR patients with poor prognosis.<\/jats:p>","DOI":"10.3324\/haematol.2025.287409","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T03:56:01Z","timestamp":1743652561000},"page":"2151-2159","source":"Crossref","is-referenced-by-count":3,"title":["Early identification of functional high-risk multiple myeloma patients after transplant: the predictive power of fat fraction and Response Assessment Category score in diffusion-weighted whole-body magnetic resonance imaging"],"prefix":"10.3324","volume":"110","author":[{"given":"Angelo","family":"Belotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Frittoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Ribolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Saeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Bianchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bottelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gullino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Chiarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Giustini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Roccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Grazioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"78953","doi-asserted-by":"crossref","unstructured":"Gay F, Bertuglia G, Mina R. A rational approach to functional high-risk myeloma. Hematology Am Soc Hematol Educ Program. 2023; 1:433-442.","DOI":"10.1182\/hematology.2023000443"},{"key":"78954","doi-asserted-by":"crossref","unstructured":"Messiou C, Kaiser M. Whole body diffusion weighted MRI--a new view of myeloma. Br J Haematol. 2015; 171(1):29-37.","DOI":"10.1111\/bjh.13509"},{"key":"78955","doi-asserted-by":"crossref","unstructured":"Messiou C, Hillengass J, Delorme S. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology. 2019; 291(1):5-13.","DOI":"10.1148\/radiol.2019181949"},{"key":"78956","doi-asserted-by":"crossref","unstructured":"Belotti A, Ribolla R, Cancelli V. Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry. Cancer Med. 2021; 10(17):5859-5865.","DOI":"10.1002\/cam4.4136"},{"key":"78957","doi-asserted-by":"crossref","unstructured":"Castagnoli F, Donners R, Tunariu N. Relative fat fraction of malignant bone lesions from breast cancer, prostate cancer and myeloma are significantly lower than normal bone marrow and shows excellent interobserver agreement. Br J Radiol. 2023; 96:20230240.","DOI":"10.1259\/bjr.20230240"},{"key":"78958","doi-asserted-by":"crossref","unstructured":"Donners R, Figueiredo I, Tunariu N. Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing. Eur Radiol. 2022; 32(7):4647-4656.","DOI":"10.1007\/s00330-022-08536-6"},{"key":"78959","doi-asserted-by":"crossref","unstructured":"Schmeel FC, Enkirch SJ, Luetkens JA. Diagnostic Accuracy of quantitative imaging biomarkers in the differentiation of benign and malignant vertebral lesions: combination of diffusion-weighted and proton density fat fraction spine MRI. Clin Neuroradiol. 2021; 31(4):1059-1070.","DOI":"10.1007\/s00062-021-01009-1"},{"key":"78960","doi-asserted-by":"crossref","unstructured":"Donners R, Blackledge M, Tunariu N. Quantitative wholebody Diffusion-weighted MR imaging. Magn Reson Imaging Clin N Am. 2018; 26(4):479-494.","DOI":"10.1016\/j.mric.2018.06.002"},{"key":"78961","doi-asserted-by":"crossref","unstructured":"Berardo S, Sukhovei L, Andorno S. Quantitative bone marrow magnetic resonance imaging through apparent diffusion coefficient and fat fraction in multiple myeloma patients. Radiol Med. 2021; 126(3):445-452.","DOI":"10.1007\/s11547-020-01258-z"},{"key":"78962","doi-asserted-by":"crossref","unstructured":"Sun M, Wang L, Wang C. Quantitative analysis of wholebody MRI for accessing the degree of diffuse infiltration patterns and identifying high risk cases of newly diagnosed multiple myeloma. J Magn Reson Imaging. 2024; 59(6):2035-2045.","DOI":"10.1002\/jmri.28962"},{"key":"78963","doi-asserted-by":"crossref","unstructured":"Takasu M, Kondo S, Akiyama Y. Assessment of early treatment response on MRI in multiple myeloma: comparative study of whole-body diffusion-weighted and lumbar spinal MRI. PLoS One. 2020; 15(2):e0229607.","DOI":"10.1371\/journal.pone.0229607"},{"key":"78964","doi-asserted-by":"crossref","unstructured":"Koutoulidis V, Terpos E, Papanikolaou N. Comparison of MRI features of fat fraction and ADC for early treatment response assessment in participants with multiple myeloma. radiology. 2022; 304(1):137-144.","DOI":"10.1148\/radiol.211388"},{"key":"78965","doi-asserted-by":"crossref","unstructured":"Latifoltojar A, Hall-Craggs M, Bainbridge A. Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. Eur Radiol. 2017; 27(12):5325-5336.","DOI":"10.1007\/s00330-017-4907-8"},{"key":"78966","doi-asserted-by":"crossref","unstructured":"Dong H, Huang W, Ji X. Prediction of early treatment response in multiple myeloma using MY-RADS total burden score, ADC, and fat fraction from whole-body MRI: impact of anemia on predictive performance. AJR Am J Roentgenol. 2022; 218(2):310-319.","DOI":"10.2214\/AJR.21.26534"},{"key":"78967","doi-asserted-by":"crossref","unstructured":"Rasche L, Chavan SS, Stephens OW. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017; 8(1):268.","DOI":"10.1038\/s41467-017-00296-y"},{"key":"78968","doi-asserted-by":"crossref","unstructured":"Moreau P, Attal M, Caillot D. Prospective evaluation of magnetic resonance imaging and [18F] fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma Included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017; 35(25):2911-2918.","DOI":"10.1200\/JCO.2017.72.2975"},{"key":"78969","doi-asserted-by":"crossref","unstructured":"Zamagni E, Nanni C, Gay F. MRD Evaluation by PET\/CT According To Deauville Criteria Combined with bone marrow techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients enrolled in the Phase II FORTE Trial. Hemasphere. 2020; 4(S1)","DOI":"10.1182\/blood-2019-125134"},{"key":"78970","doi-asserted-by":"crossref","unstructured":"Rasche L, Alapat D, Kumar M. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019; 33(7):1713-1722.","DOI":"10.1038\/s41375-018-0329-0"},{"key":"78971","doi-asserted-by":"crossref","unstructured":"Agazzi GM, Di Meo N, Rondi P. Fat fraction extracted from whole-body magnetic resonance (WB-MR) in bone metastatic prostate cancer: intra- and inter-reader agreement of single-slice and volumetric measurements. Tomography. 2024; 10(7):1014-1023.","DOI":"10.3390\/tomography10070075"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12011\/78271","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12011\/78743","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12011\/78271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:30Z","timestamp":1794046110000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.287409","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,3]]}}}